Advances in medical treatment of cushing's disease

Expert Review of Endocrinology and Metabolism

Volumn 2, Issue 6, 2007, Pages 735-743

  Arnaldi, Giorgio ^a   Cardinaletti, Marina ^b   Boscaro, Marco ^b  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Cabergoline; Cushing's disease; Neuromodulators; Pasireotide (SOM230); Retinoid acid; Steroidogenesis inhibitors; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMINOGLUTETHIMIDE; ANDROGEN; ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ETOMIDATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETANSERIN; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PASIREOTIDE; PERGOLIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROGESTERONE RECEPTOR; RETINOIC ACID; RITANSERIN; ROSIGLITAZONE; SEROTONIN ANTAGONIST; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNINDEXED DRUG;

ACNE; ADRENALECTOMY; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; BLURRED VISION; BONE MARROW TOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFUSION; CUSHING DISEASE; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; EDEMA; FATIGUE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEART FAILURE; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; HYPOGONADISM; HYPOKALEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHYROIDISM; INJECTION SITE REACTION; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; MORBIDITY; NAUSEA; NEUROLOGIC DISEASE; NEUROMODULATION; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN;

EID: 36148963639     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.2.6.735     Document Type: Review

References (77)

1. Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88(12), 5593-5602 (2003).
2. Bourdeau I, Bard C, Forget H, Boulanger Y, Cohen H, Lacroix A. Cognitive function and cerebral assessment in patients who have Cushing's syndrome. Endocrinol. Metab. Clin. North Am. 34(2), 357-369 (2005).
3. Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary 7(4), 253-256 (2004).
4. Mancini T, Doga M, Mazziotti G, Giustina A. Cushing's syndrome and bone. Pituitary 7(4), 249-252 (2004).
5. Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the Furopean Cushing's Disease Survey Group. J. Clin. Endocrinol. Metab. 80(11), 3114-3120 (1995).
6. Hammer GD, Tyrrell JB, Lamborn KR et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J. Clin. Endocrinol. Metab. 89(12), 6348-6357 (2004).
7. Hofmann BM, Fahlbusch R. Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. Front. Horm. Res. 34, 158-184 (2006).
8. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin. Endocrinol. (Oxford) 63(5), 549-559 (2005).
9. Castinetti F, Nagai M, Dufour H et al. γ knife radiosurgery is a successful adjunctive treatment in Cushing's disease. Eur J Endocrinol. 156(1), 91-98 (2007).
10. Gumbs AA, Gagner M. Laparoscopic adrenalectomy. Best Pract. Res. Clin. Endocrinol. Metab. 20(3), 483-499 (2006).
11. Assie G, Bahurel H, Coste J et al. Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J. Clin. Endocrinol. Metab. 92(1), 172-179 (2007).
12. Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocr. Rev. 14(4), 443-458 (1993).
13. Sonino N, Boscaro, M. Medical therapy for Cushing's disease. Endocrinol. Metab. North Am. 28, 211-222 (1999).
14. Nieman LK. Medical therapy of Cushing's disease. Pituitary 5(2), 77-82 (2002).
15. Morris D, Grossman A. The medical management of Cushing's syndrome. Ann. NY Acad. Sci. 970, 119-133 (2002).
16. Sonino N, Boscaro M, Fallo F. Pharmacologic management of Cushing syndrome. Treat. Endocrinol. 4(2), 87-94 (2005).
17. Trincali G, Aubry JM, Moscianese K et al. Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission. J. Psychiatry Neurosci. 29(6), 459-466 (2004).
18. Krieger DT, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing's disease. N. Engl. J. Med. 293(18), 893-896 (1975).
19. Sonino N, Fava GA, Fallo F, Franceschetto A, Belluardo P, Boscaro M. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary 3(2), 55-59 (2000).
20. Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat. Med. 8(11), 1281-1287 (2002).
21. Emery MN, Leontiou C, Bonner SE et al. PPAR-γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-γ receptor. Clin. Endocrinol. (Oxford) 65(3), 389-395 (2006).
22. Heaney AP, Novel medical approaches for the treatment of Cushing's disease. J. Endocrinol. Invest. 27(6), 591-595 (2004).
23. Ambrosi B, Dall'Asta C, Cannavo S et al. Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease. Eur. J. Endocrinol. 151(2), 173-178 (2004).
24. Giraldi FP, Scaroni C, Arvat E et al. Effect of protracted treatment with rosiglitazone, a PPAR-γ agonist, in patients with Cushing's disease. Clin. Endocrinol. (Oxford) 64(2), 219-224 (2006).
25. Cannavo S, Arosio M, Almoto B, Dall'Asta C, Ambrosi B. Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease. Clin. Endocrinol. (Oxford) 63(1), 118-119 (2005).
26. Cannavo S, Ambrosi B, Chiodini I et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-γ ligand, rosiglitazone, in Cushing's disease. J. Endocrinol. Invest. 27(5), RC8-R11 (2005).
27. Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J. Clin. Endocrinol. Metab. 90(3), 1340-1346 (2005).
28. Barbaro D, Lapi P, Orsini P, Pasquini C, Ciaccio S. Pioglitazone treatment in Cushing's disease. J. Endocrinol. Invest. 28(4), 388-389 (2005).
29. Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB. The PPAR-γ activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clin. Endocrinol. (Oxford) 64(5), 519-522 (2006).
30. Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J. Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J. Clin. Endocrinol. Metab. 92(5), 1758-1763 (2007).
31. Pivonello R, Ferone D, de Herder WW. Dopamine receptor expression and function in corticotroph pituitary tumors. J. Clin. Endocrinol. Metab. 89(5), 2452-2462 (2004).
32. T'Sjoen G, Defeyter I, Van De Saffele J, Rubens R, Vandeweghe M. Macroprolactinemia associated with Cushing's disease, successfully treated with cabergoline. J. Endocrinol. Invest. 25(2), 172-175 (2002).
33. Miyoshi T, Otsuka F, Takeda M et al. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J. Endocrinol. Invest. 27(11), 1055-1059 (2004).
34. Illouz F, Dubois-Ginouves S, Laboureau S, Rohmer V, Rodien P. Use of cabergoline in persisting Cushing's disease. Ann. Endocrinol. (Paris) 67(4), 353-356 (2006).
35. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao, A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J. Endocrinol. Invest. 22(11), 860-865 (1999).
36. Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm. Res. 62(6), 300-305 (2004).
37. Godbout A, Beauregard H, Babin S, Sabourin A, Lacroix A. Cabergoline in the long-term treatment of Cushings disease. Proceedings of the Endocrine Society's 89th Annual Meeting. Toronto, Canada, 2-5 June 2007 (Abstract P4-51).
38. Pivonello R, De Martino MC, Faggiano A et al. Cabergoline treatment in Cushings disease: effect on hypertension, glucose intolerance and dyslipidemia. Proceedings of the Endocrine Society's 89th Annual Meeting. Toronto, Canada, 2-5 June 2007 (Abstract P4-50).
39. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356(1), 39-46 (2007).
40. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356(1), 29-38 (2007).
41. Roth BI. Drugs and valvular heart disease. N. Engl. J. Med. 356(1), 6-9 (2007).
42. van der Hoek J, Lamberts SW, Hofland LJ. The role of somatostatin analogs in Cushing's disease. Pituitary 7(4), 257-264 (2004).
43. Arnaldi G, Polenta B, Cardinaletti M, Boscaro M. Potential indications for somatostatin analogs in Cushing's syndrome: J. Endocrinol. Invest. 28(11 Suppl. International), 106-110 (2005).
44. Vignati F, Loli P. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J. Clin. Endocrinol. Metab. 81(8), 2885-2890 (1996).
45. Stalla GK, Brockmeier SJ, Renner U et al. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur. J. Endocrinol. 2, 125-131 (1994).
46. van der Hoek J, Waaijers M, van Koetsveld PM et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am. J. Physiol. Endocrinol. Metab. 289(2), E278-E287 (2005).
47. Strowski MZ, Dashkevicz MP, Parmar RM et al. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 6, 339-346 (2002).
48. Cervia D, Nunn C, Fehlmann D, Langenegger D, Schuepbach E, Hoyer D. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br. J. Pharmacol. 1, 109-121 (2003).
49. Hofland LJ, van der Hoek J, Feelders R et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur. J. Endocrinol. 152(4), 645-654 (2005).
50. Batista DL, Zhang X, Gejman R et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J. Clin. Endocrinol. Metab. 91(11), 4482-4488 (2006).
51. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146(5), 707-716 (2002).
52. Silva AP. Schoeffter P, Weckbecker G, Bruns C, Schmid HA. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur. J. Endocrinol. 153(3), R7-R10 (2005).
53. Boscaro M, Petersenn S, Atkinson AB et al. Pastreotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushings disease: preliminary safety and efficacy results of a Phase II study. Proceedings of the Endocrine Society's 88th Annual Meeting. Boston, MA, USA 24-27 June 2006 (Abstract OR9-1).
54. Unger N, Helmut T, Schultz S, Wolfgang S, Klaus M, Petersenn S. Differential expression of somatostatin receptor subtypes 1-5 proteins in numerous normal human tissues. European Congress of Endocrinology [Abstract P1-192) (2005).
55. Paez-Pereda M, Kovalovsky D, Hopfner U et al. Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest. 108(8), 1123-1131 (2001).
56. Lauber M, Theodoropoulou M, Sievers C. New aspects in the diagnosis and treatment of Cushing disease. Front. Horm. Res. 35, 169-178 (2006).
57. Castillo V, Giacomini D, Paez-Pereda M et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 147(9), 4438-4444 (2006).
58. Luton JP, Mahoudeau JA, Bouchard P et al. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. N. Engl. J. Med. 300(9), 459-464 (1979).
59. Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin. Endocrinol. (Oxford) 35(4), 347-352 (1991).
60. Stiefel P, Garcia-Morillo JS, Jimenez L et al. Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in non ectopic Cushing's syndrome. Endocrine 18(3), 279-284 (2002).
61. Smagin GN, Goeders NE. Effects of acute and chronic ketoconazole administration on hypothalamo-pituitary-adrenal axis activity and brain corticotropin-releasing hormone. Psychoneuroendocrinology 29(10), 1223-1228 (2004).
62. Deuschle M, Lecei O, Stalla GK et al. Steroid synthesis inhibition with ketoconazole and its effect upon the regulation of the hypothalamus-pituitary-adrenal system in healthy humans. Neuropsychophamacology 28(2), 379-383 (2003).
63. Boscaro M, Sonino N, Rampazzo A, Mantero F. Response of pituitary-adrenal axis to corticotrophin releasitig hormone in patients with Cushing's disease before and after ketoconazole treatment. Clin. Endocrinol. (Oxford) 27(4), 461-467 (1987).
64. Inagaki M, Akizuki N, Kugaya A, Fujii H, Akechi T, Uchitomi Y. Metyrapone for Cushing's syndrome. Am. J. Pshchiatry 159(7), 1246 (2002).
65. Beardwell CG, Adamson AR, Shalet SM. Prolonged remission in florid Cushing's syndrome following metyrapone treatment. Clin. Endocrinol. (Oxford) 14(5), 485-492 (1981).
66. Sonino N, Boscaro M, Ambroso G, Merola G, Mantero F. Prolonged treatment of Cushing's disease with metyrapone and aminoglutethimide. IRCS Med. Sci. 14, 485-486 (1986).
67. Cheng VY, Martin LJ, Elliott EM et al. α5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J. Neurosci. 26(14), 3713-3720 (2006).
68. Li GD, Chiara DC, Sawyer GW, Husain SS, Olsen RW, Cohen JB. Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. J. Neurosci. 26(45), 11599-11605 (2006).
69. Zeller A, Arras M, Jurd R, Rudolph U. Mapping the contribution of β3-containing GABAA receptors to volatile and intravenous general anesthetic actions. BMC Pharmacol. 7, 2 (2007).
70. Allolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hancke C, Winkeimann W. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin. Wocherschr. 66(8), 361-364 (1988).
71. Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and doseresponse relationship in normal subjects. J. Clin. Endocrinol. Metab. 70(5), 1426-1430 (1990).
72. Greening JE, Brain CE, Perry LA et al. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's diseae. Horm. Res. 64(3), 140-143 (2005).
73. Johnson TN, Canada TW. Etomidate use for Cushing's syndrome caused by an ectopic adrenocorticotropic hormone-producing tumor. Ann. Pharmacother. 41(2), 350-353 (2007).
74. Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J. Clin. Endocrinol. Metab. 86(19), 4104-4108 (2001).
75. Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J. Clin. Endocrinol. Metab. 83(10), 3542-3544 (1988).
76. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepeistone (RU 486). J. Clin. Endocrinol. Metab. 86(8), 3568-3573 (2001).
77. Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing's syndrome. N. Engl. J. Med. 352(23), 2457-2458 (2005).